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Abstract 
Background: While there is an increasing consensus that clinical trial 
results should be shared with trial participants, there is a lack of 
evidence on the most appropriate methods. The aim of this Study 
Within A Trial (SWAT) is to use a patient and public involvement (PPI) 
approach to identify, develop and evaluate a patient-based approach 
to receiving trial results for participants in the Thyroid Hormone 
Replacement for Subclinical Hypo-Thyroidism Trial (TRUST), a trial of 
thyroxine versus placebo in people aged 65 years and older. 
Methods: Mixed methods study with three consecutive phases. Phase 
1 iteratively developed a patient-based approach using semi-
structured focus groups and a consensus-orientated-decision model, 
a PPI group to refine the method and adult literacy review for plain 
English assessment. Phase 2 was a single-blind parallel group trial. 
Irish TRUST participants were randomised to the intervention (patient-
based approach) and control group (standard approach developed by 
lead study site). Phase 3 used a patient understanding questionnaire 
to compare patient understanding of results between the two groups. 
Results: Participants want to receive results of clinical trials, with 
qualitative findings indicating three key themes including 
‘acknowledgement of individual contribution’, ‘contributing for a 
collective benefit’ and ‘receiving accessible and easy to understand 
results’. Building on these findings, the patient-based approachwas 
developed. TRUST participants (n=101) were randomised to the 
intervention (n=51) or control group (n=50). The questionnaire 
response rate was 74% for the intervention group and 62% for the 
control group.  There were no differences in patient understanding 
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between the two approaches.  
Conclusions: We have demonstrated that it is feasible to involve trial 
participants in the development of result dissemination materials. 
Although, in this study PPI did not influence patients’ understanding 
of results, it documents the process of conducting PPI within the 
clinical trial setting.
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sufficient regardless of any pragmatic impact. However, PPI costs 
time and money, therefore pragmatic claims need scrutiny8. More 
substantive evidence is needed to evaluate the potential impact 
of PPI on the conduct and outcomes of research5,9. In 2001, 
the need to establish if PPI leads to actual, rather than merely 
perceived benefits for research processes and output was 
identified. Over fifteen years later, this need remains.
In clinical research, the results of clinical trials have not 
traditionally been shared with clinical trial participants. A recent 
survey carried out on a large registry of health research partici-
pants, found that while 95.6% of respondents said researchers 
should always or sometimes offer the results to participants, 
only 33% of respondents actually received the results of studies 
in which they had participated10. An upcoming European Union 
Clinical Trial Regulation requires sponsors to provide sum-
mary results of clinical trials in a format understandable to 
laypersons, including participants11. However, there is a lack 
of evidence on the most appropriate methods of sharing results 
with participants. Uncertainty persists around what information 
should be shared, how results should be shared and who should 
be responsible for sharing the results. Since the findings of 
clinical research often exist in a complex context of scientific 
exchange and debate, it is important that the information shared 
is accessible and relevant to participants12. The increasing 
understanding of the importance of sharing research results with 
study participants is somewhat linked to a wider movement 
towards transparency in trials. This movement is largely pro-
moted by initiatives such as SPIRIT, CONSORT and AllTrials. 
The SPIRIT Statement provides guidance to researchers to 
improve the completeness and quality of trial protocols13, the 
Consolodated Standards of Reporting Trials (CONSORT) State-
ment is an evidence based, minimum set of recommendations for 
reporting randomised trials14 and the AllTRials iniative calls for 
all past and present triasl to be registered and their full methods 
and summary results reported15. Some of these initiatives also 
include recommendations for disseminating results to research 
participants. For example, the SPIRIT statement states that study 
results must be released to participating physicians, referring 
physicians, patients and the general medical community13.
The Thyroid Hormone Replacement for Subclinical Hypothy-
roidism Trial (TRUST) was a multi-centre, double blind, 
placebo controlled, phase III clinical trial testing the efficacy of 
thyroxine replacement in subclinical hypothyroidism in older 
community dwelling adults16. The results of the TRUST trial 
were published in the New England Journal of Medicine on 3rd of 
April, 201716. This Study Within A Trial (SWAT) was 
conducted at the Irish TRUST trial site prior to and after pub-
lication of results. The aim of this SWAT was to investigate 
methods of disseminating trial findings to participants by using 
a PPI approach to identify, develop and evaluate a patient-based 
approach of receiving trial results.
Methods
Study design
This was a sequential mixed methods study with three phases. In 
this study, methods were combined for complementarity, where 
            Amendments from Version 1
This improved version contains some minor revisions as 
suggested by peer-reviewers.
Throughout the manuscript, the following changes have been 
made:
•    “patient- preferred” has been changed to “patient-based”.
•    “patient-preferred method” has been changed to “patient-
based approach”.
•    “Standard method” has been changed to “standard 
approach”.
Within the Abstract, the aim of the study has been re-worded to 
clarify that all TRUST participants were aged 65 and over.
Within the Introduction section, additional background information 
has been provided on the need to evaluate the impact of PPI. This 
serves as a rationale for doing the study. We have also introduced 
the recent movement towards transparency in trials including 
references to the SPIRIT, CONSORT and AllTrials initiatives.
Within the Methods section, additional details have been 
provided on the PPI group and how PPI partners were identified 
and recruited. Further information has also been provided on 
the Consensus Oriented Decision Making (CODM) model and 
how the model was specifically used in this study. We have also 
provided a clear distinction between adult literacy and health 
literacy.
Within the Results section, a footnote has been added to Table 1 
to clarify that only a subgroup of Irish participants were invited to 
the focus groups. A footnote has also been added to Table 2 to 
clarify how patient understanding was assessed.
Within the Discussion, the section entitled ‘Limitations of the 
study’ has now been reworded to ‘Strengths and limitations of the 
study’ and the paragraph that discusses how PPI partners were 
participants in the trial has been rephrased as a strength of the 
study.
See referee reports
REVISED
Introduction
Patient and public involvement (PPI) is increasingly recognised 
as an essential component of clinical research. In the UK, the 
national advisory group supporting active public involvement 
in health services, public health and social care research 
(INVOLVE) defines PPI as ‘research being carried out ‘with’ or 
‘by’ members of the public rather than ‘to’ ‘about’ or ‘for’ them’1. 
In clinical trials, PPI has been defined as experimenting with 
participants instead of experimenting on participants2. PPI may 
occur at any stage during the research process from priority 
setting and drafting study protocols right through to conducting 
the study, interpreting the end results and communicating and 
disseminating research findings3,4. Research funders increasingly 
expect that PPI is prioritised and resourced within studies. This 
increasing expectation has heightened the risk of researchers car-
rying out ‘tick-box’ PPI rather than ‘meaningful’ involvement5. 
There are many moral and ethical arguments being made for 
PPI. Many believe that as citizens and taxpayers, members of 
the public have a right to influence research that is being funded 
by public money6. PPI researchers are also making pragmatic 
arguments for PPI and providing anecdotal accounts about how 
PPI can make research more relevant, accessible and accept-
able to participants7. The ethical arguments are often seen as 
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each method addressed a different aspect of the study aim17. The 
first phase used a qualitative approach to identify and develop a 
patient-based approach to disseminating the results, the second 
phase used a SWAT intervention to compare the dissemination 
approaches and the third phase used a quantitative patient under-
standing questionnaire to evaluate the patient-based approach. 
The full study protocol has been published elsewhere18, but a 
summary follows here.
Setting
The study sites for the TRUST trial were the University of 
Glasgow, Scotland (lead site); Leiden Academy on Vitality and 
Ageing, The Netherlands; Leiden University Medical Centre, The 
Netherlands; University of Berne, Switzerland; and University 
College Cork, Ireland. A total of 738 participants with subclinical 
hypothyroidism were recruited to the trial over a three-and-a-
half year period from 2013–201716. The trial completed recruit-
ment in November 2016 and the results were published in 
April 201716.
This SWAT was conducted at the Irish TRUST site. The hub 
centre for the Irish TRUST site was located at the Mercy 
University Hospital, Cork where 38 participants were recruited. 
A further 77 participants were recruited from five satellite sites.
Population
As this SWAT was embedded in an ongoing clinical trial the 
study sample was determined by the TRUST Thyroid trial. There 
were 115 TRUST participants recruited in the Irish site, 11 of 
these participants withdrew over the course of the trial. Our study 
sample included all remaining TRUST participants (n=104).
Phase One: Identification and development of 
patient-based approach (qualitative and PPI phase)
The first phase of the study used a qualitative approach to 
iteratively identify and develop a patient-based approach to 
disseminate the results of TRUST trial. This was done in three 
separate stages: qualitative focus groups, a PPI group and an 
adult literacy review.
Focus groups
Three semi-structured focus groups were conducted with four 
to eight TRUST trial participants per group. All Cork-based 
patients (n = 38) were contacted via letter and invited to 
participate. A €20 shopping voucher was given to all participants 
to cover travel expenses. Each session was led by trained quali-
tative researchers (WHS, ER, CH). A topic guide was used to 
guide the focus groups. The topic guide was reviewed and refined 
by all members of the SWAT research team (see Supplementary 
File 1: Focus group topic guide).
The Consensus-Oriented-Decision-Making (CODM) model 
was used to guide the group to reach a consensus19. The CODM 
model is accepted as a flexible model for reaching decisions19. 
In this study some of the steps were initiated by the focus group 
facilitator and others occurred naturally as a follow on from 
the previous step. Below is an outline of each of the seven 
steps of the CODM model and how they were used in this study:
1.    Framing the topic: The focus group facilitator intro-
duced the idea of sharing results with participants and 
provided some context on the reasons why results are/ are 
not shared with participants.
2.    Open discussion: The facilitator asked the group 
whether or not they think results should be shared with 
trial participants and whether or not they would like to 
receive the results of the TRUST trial.
3.    Identifying underlying concerns: The previous discussion 
naturally followed on to participants asking questions 
and expressing concerns about the result method, content 
and language that would be used.
4.    Collaborative proposal building: The group worked 
together to agree on the important elements of the results 
in terms of result method, content and language.
5.    Choosing a direction: This step occurred naturally as 
part of the previous step.
6.    Synthesizing a final proposal: The facilitator re-iterated 
the proposal the group had agreed upon and asked the 
group for feedback.
7.    Closure: This step occurred naturally as part of the 
previous step.
Analysis. Focus group recordings were transcribed verbatim 
and entered into NVivo Version 11 for data management 
during thematic analysis. Braun and Clarke guidelines20 for 
conducting thematic analysis were followed. Initial focus group 
transcripts were analysed independently by two researchers 
(ER and AC). Each transcript was read multiple times (data 
familiarisation) and initial codes were identified. These codes 
were then used to identify emerging themes. Both researchers 
discussed emerging themes and conducted further refinement. 
The refined themes were then discussed and agreed upon with 
other members of the research team (ER, CH, AC, KMS). 
Researchers (ER, CH, AC) then used the focus group findings 
to develop an initial draft of a patient-based approach for the 
dissemination of results (see Supplementary File 2: Draft one of 
patient-based result letter).
PPI group
A PPI group was established to develop and refine the 
content of the patient-based appproach for the dissemination of 
results. During the focus groups, three TRUST trial participants 
volunteered to take part in the PPI group. In addition to these 
three PPI partners, an additional partner was identified from a 
previous qualitative research study undertaken by the research 
team. This individual was keen to learn more about research 
and expressed an interest in being involved in future projects. 
While this individual had previous experience of taking part in 
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research (as an interview participant), she had no experience of 
taking part in a clinical trial or being involved as a PPI partner. 
Originally, we intended to conduct these sessions in a group 
format, due to difficulties with PPI partners’ schedule commit-
ments, one-to-one sessions were conducted. At the one-one 
session, a researcher (ER) and the PPI partner discussed the 
layout, content and language of the initial draft of the result 
method. Researchers and PPI partners worked together to edit 
different sections of the document. These discussions were not 
audio recorded but comprehensive field notes were taken by the 
researcher (ER). These notes were then collated by the researcher 
and used to further ensure that the results letter reflected 
PPI partners’ perspectives and preferences.
Adult literacy review
While the PPI group had significant input into the format and 
language used in the patient-based approach, the research team 
felt that it would be of additional benefit to collaborate with the 
National Adult Literacy Agency (NALA) to ensure the document 
adhered to national “Plain English” standards. These standards 
ensured that the information presented to trial participants was 
sufficiently easy to read and understand (literacy). This would 
help to ensure that trial participants were able to make sound 
health decisions based on the information presented (health 
literacy)21. This review was an iterative process with several 
drafts exchanged for editing. Although the review was taken as an 
additional step to the published protocol for the study, the research 
team felt it was helpful to further ensure that the document 
was accessible and easy to understand.
At the end of the first phase of the study, a final draft of the 
patient-based result letter was approved by researchers, PPI group 
and adult literacy experts (see Supplementary File 3: Final draft 
of patient-based result letter).
Phase Two: Dissemination of trial results 
(intervention phase)
The second phase of the study used a SWAT intervention to 
disseminate the results of the TRUST Thyroid Trial to trial par-
ticipants. This was done using a prospective, randomised, single 
blind, parallel trial design. It is important to note that when the 
term randomisation is used, it refers to the allocation of patients 
to intervention/control within the SWAT and not the TRUST 
Thyroid trial. Irish TRUST participants were randomised to 
intervention or control groups using an online random number 
generator. The intervention group received the patient-based letter 
format (see Supplementary File 3: Final version patient-based 
results letter) and the control group received a copy of the 
TRUST results press release, which was made available by 
the lead study site on the TRUST Thyroid Trial Website (see 
Supplementary File 4: Standard results letter). Participants 
were blinded to their intervention group. One member of 
the research team was un-blinded in order to perform the 
randomisation and distribute the results of the trial. As they 
were un-blinded to perform these two important tasks, they 
were not involved in the data analysis or interpretation in 
any way.
Phase Three: Evaluation of patient –based approach 
(quantitative phase)
The third phase of the study used a quantitative patient under-
standing questionnaire to evaluate the patient-based approach 
to disseminating trial results. The questionnaire was developed 
in consultation with experts in the area of subclinical hypothy-
roidism and scale (questionnaire) development (PK and KMS). 
The early development of the questionnaire was guided by a 
consultation document, which accompanies the EU Clinical 
Trials Regulation No 536/201422. This document highlights the 
information which should be presented to trial participants in 
the trial summary at the end of a trial. However, initial question-
naire items were modified to allow for psychometric testing. 
The final questionnaire contained 12 questions; six items were 
measured on a five point LIKERT scale, there were four 
multiple-choice questions and two vignettes. The first six items 
measured patients’ perceived understanding of results, the four 
multiple choice measured patients’ actual understanding of 
results by requiring them to select the correct answer. To further 
test participants’ understanding of the trial results, two vignettes 
describing two typical patient case studies of older adults with 
subclinical hypothyroidism were provided with a question 
on whether a doctor should prescribe thyroxine for the hypo-
thetical patient described. The questionnaire was reviewed by 
the PPI group to assess content and face validity. It then under-
went further review by NALA to ensure adherence to the national 
‘Plain English’ standard. The final version of the questionnaire 
can be seen in Supplementary File 5: Patient understanding 
questionnaire.
The questionnaire was sent to all Irish TRUST participants 
(intervention and control group) one week after they received 
the results of the trial. A reminder questionnaire was sent to 
non-responders 3 weeks later.
Analysis. The primary outcome was the difference in levels 
of patient understanding between the intervention and control 
groups. This measured the impact of PPI on patient understand-
ing of end of trial results. The psychometric properties and 
construct validity of the questionnaire were examined with 
exploratory factor analysis. Principal component analysis (PCA) 
was conducted on the six LIKERT scale items. Internal consist-
ency of the questionnaire was investigated using Cronbach’s 
alpha coefficient. Completed questionnaires were entered into 
SPSS software (version 24) and analysed using descriptive and 
inferential (Chi-square test and Fishers Exact) statistics. The 
researcher carrying out data input and analysis was blinded to 
the participants’ allocation status.
Costs of conducting PPI
The lead researcher (ER) kept a detailed account of all direct 
costs associated with conducting PPI for the purpose of this 
study. These costs included researcher salary, travel and expenses 
for PPI participants, adult literacy review and printing and 
postage costs.
This paper has been written in adherence to the Guidance for 
Reporting Involvement of Patients and Public 2 (GRIPP 2)23. 
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The GRIPP 2 checklist is a tool, developed to improve the report-
ing of patient and public involvement in research and guide 
the development of a transparent, consistent and high-quality 
PPI evidence base. The Good Reporting of a Mixed Methods 
Study (GRAMMS) framework was also used to inform the 
reporting of the findings24.
Results
Characteristics of the trial participants stratified by participation 
in the different stages of the study are presented in Table 1.
Phase One: Identification and development of 
patient-based approach (qualitative and PPI phase)
Focus groups
Three focus groups were held with 19 out of 38 participants 
accepting an invitation to join. Participants who attended the focus 
groups were similar in age, gender, education level to those who 
did not attend.
Focus group findings indicate that participants want to receive 
the results of the trial in which they are taking part. Three main 
themes emerged in relation to participants’ perspectives of and 
preferences for receiving trial results: ‘acknowledgement of indi-
vidual contribution’, ‘contributing for a collective benefit’ and 
‘receiving accessible and easy to understand results’.
Acknowledgement of individual contribution
Many participants reported feeling they had made an individual 
contribution to the trial in terms of their time and personal infor-
mation while attending the trial study visits. As such, participants 
felt that receiving the results of the trial would provide an 
acknowledgement of this individual contribution:
‘Yes,Imeanit’skindofinstinctive…whenyougointoa[clini-
caltrial]andyouspendandinvestthattimeinit.Imeanokay
I had the time to invest but you knowat the endof theday,
[receivingtheresult]iskindoflikeyourpayoff.’ (FG2 P3)
Contributing for a collective benefit
While participants spoke about making an individual contribu-
tion to the trial, they felt that their involvement contributed to a 
collective benefit or greater good. Participants reported that 
receiving the results of the trial would help them to feel that they 
had contributed to this greater good:
‘I’m not really interested in my own personal results but
as the results of the scheme as a whole.You know the idea
is, does the study help or hinder old people and that’s
whatIwanttoknow’ (FG2 P1)
This feeling of contributing for a collective benefit was further 
reinforced when participants discussed their desire to understand 
how the results of the trial will be implemented by medical experts 
and ultimately how it will affect others who have the condition:
‘I would like to know, if they found out, okay, do we treat
these people or not.Thatwould be good.Dowe treat them
or don’t we treat them? I think that is what it’s all about’
(FG3P4)
Receiving accessible and easy to understand results
Participants expressed a clear need to receive the results of the 
trial in an accessible and easy to understand way. This preference 
applied to the format, language and content of the patient-based 
approach.
Table 1. Characteristics of trial participants stratified by participation in the different stages of the study.
Total Irish 
TRUST 
participants 
(n=104)
Attended 
SWAT focus 
groups1 (n=19) 
Total Sample 
n=38 RR2 =50%
Randomised3 (n=101)
Returned SWAT 
questionnaire (n=69) 
Total Sample n=101 RR2=68%
Intervention 
Group (n=51)
Control 
Group (n=50)
Intervention 
Group (n=38) 
RR= 74%
Control 
Group (n=31) 
RR=62%
Sex 
   Male 61 (58.7%) 14 (73.7%) 31 (60.8%) 28 (56%) 26 (68%) 16 (52%)
   Female 43 (41.3) 5 (26.3%) 20 (39.2%) 22 (44%) 12 (32%) 15 (48%)
Age 
   65–74 57 (54.8%) 12 (63.1%) 32 (62.7%) 24 (48%) 25 (66%) 12 (45%)
   75+ 47 (45.2%) 7 (36.9%) 19 (37.3%) 26 (52%) 13 (34%) 17 (55%)
Education 
   Primary only 22 (21.2%) 2 (10.5%) 12 (23.6%) 9 (18%) 10 (26%) 8 (26%)
   Secondary/Tertiary 47 (45.1%) 12 (63.2%) 24 (47.1%) 22 (44%) 19 (50%) 11 (35%)
   Unknown 35 (33.7%) 5 (26.3%) 15 (29.3%) 19 (38%) 9 (24%) 12 (39%)
1A subgroup of Irish TRUST participants (n=38) were invited to focus groups.
2RR=Response Rate
3Total Irish TRUST participants (n=104) excluding PPI partners (n=3)= n=101.
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The majority of participants said they would like to receive 
the results in a letter format posted to them directly from the 
TRUST trial. Participants felt that this method would be acces-
sible to them as they could read the results ‘in text’ (FG3 P4) 
and keep a ‘hardcopy’ (FG P1). While participants wanted an 
official statement of the results in a letter format, they also felt 
it was important to add a personal element to the letter. They 
suggested this could be done by offering participants a phone 
number that they could call if they wished to discuss any further 
issues or concerns with the TRUST study team:
‘Could you attach a helpline on to it? If you know, some-
body had some kind of serious medical question or that
they thought was a bit personal element or whatever. That
they’d like to talk to amedical person or whatever. Instead
of just talking to your GP, maybe that would add another
dimensionofcarearoundtheTRUST’ (FG2 P3)
Participants agreed that the format, content and language of 
the results letter needed to be easy to read and understand. All 
participants wanted the letter to be no longer than 2–3 pages 
and presented in a question and answer format. Participants 
believed the content of the results letter should include ‘pertinent
information’ (FG1 P7) relating to the trial itself, the study drug 
(including side effects) and the results of the trial. They stressed 
the importance that this information needed to be informed 
by medical experts and ‘from a good authoritative source’ 
(FG2 P2) but it should be presented to them in a language that 
fits their current context and could be easily understood by 
those who do not have scientific or medical backgrounds.
‘Just in ordinary language that we can understand
ourselves, youknow thatwedon’twantbigand longexpla-
nationor that, just thatwecanpick itupstraightaway that
it’swithout any huge number of pages. Just the bare, tome
anyway,answerstothequestions.’ (FG3- P2)
It was evident from the focus groups that participants want to 
receive the results of the trial both to acknowledge their indi-
vidual contribution to the trial and also help them to feel that 
they had contributed to a greater good. Participants expressed a 
clear preference to receive the results in an accessible and easy 
to understand way. These results were used by the researcher 
(ER) to develop an initial draft of the results letter (see 
Supplementary File 2: Draft one patient-based result letter).
PPI group
The initial draft of the results letter was then further iteratively 
developed by the PPI group. There were four PPI partners in 
total (three trial participants and one older adult) Each partner 
toook part in one-to-one session. Each session contained an 
open discussion between the researcher (ER) and PPI partners 
on the layout, content and language of the document. Research-
ers and PPI partners worked together to write, re-write, edit and 
change different sections of the document.
Health literacy review
This draft was then iteratively reviewed and approved by health 
literacy experts from the NALA (see Supplementary File 3: Final 
version patient-based results letter).
Phase Two: Dissemination of trial results 
(intervention phase)
There were a total of 101 Irish TRUST participants randomised 
to the SWAT intervention. Trial participants from the PPI group 
(n = 3) were excluded from randomisation as they reviewed the 
content of the intervention method prior to the intervention. 
The intervention group (n=51) received the patient-based letter 
format (see Supplementary File 3: Final version patient-based 
results letter) and the control group (n=50) received a copy of 
the TRUST results press release, which was made available 
by the lead study site on the TRUST Thyroid Trial Website 
(see Supplementary File 4: Standard results letter).
Phase Three: Evaluation of patient-based approach 
(quantitative phase)
The overall response rate for the patient understanding question-
naire was 68% (69/101). The response rate for the intervention 
group was 74% (38/51) and the response rate for the control 
group was 62% (31/50). There were no significant differences 
in age, gender and education between those who returned the 
questionnaire and those who did not.
Post hoc power calculations showed that the study was under-
powered to detect an effect. Power for each of the patient 
understanding components ranged from .01 to. 58.
Table 2 below shows the results of patients’ perceived under-
standing of the purpose and context of the TRUST Thyroid 
Trial. Due to low participant numbers across the five Likert 
responses, the questionnaire response bands have been contracted 
from ‘Strongly Agree’ and ‘Agree’ to ‘Yes, ‘Strongly Disagree’ 
and ‘Disagree’ to ‘No’ and ‘Neither agree nor disagree’ to ‘Neutral’. 
The results show that patients’ perceptions of understand-
ing are similar between the intervention and control groups. 
Subgroup analysis showed patient’s understanding was not 
significantly impacted by age, gender or educational level.
Figure 1 shows patients’ actual understanding of the primary 
aim, side effect and results of the TRUST Thyroid Trial. Almost 
82% (n=31) of the intervention group and 65% (n=20) of the 
control group correctly understood the primary aim of the 
TRUST trial (p=0.108). Almost 40% (n=15) of the intervention 
group and 36% (n=9) of the control group correctly understood 
the associated side effects of the active drug (p=0.734). In total 
50% of the intervention group (n=19) and 58% of the control 
group correctly understood the results of the trial (p=0.504). 
There were no differences in patient understanding of trial results 
between the intervention and control groups.
In terms of patient understanding of hypothetical patient case 
studies, 43% (n=13) of the intervention group gave the correct 
answer to Vignette A; this was lower than the control group 
(62.1%, n=18, p=0.15). In total 77% (n=23) of the intervention 
group gave the correct answer to Vignette B, this was higher than 
the control group (66%, n=19, p=0.344).
Psychometric testing
An exploratory principal components analysis (PCA) was con-
ducted on the patient understanding questionnaire to determine 
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Table 2. Patient perceptions of understanding presented by group1.
Item Group Yes No Neutral p-value
I understand why the TRUST Thyroid Trial took place. Intervention 
(n=38)
37 
(97.4%)
1 
(2.6%)
0 
(0%)
0.584
Control (n=31) 29 (93.5%)
2 
(6.5%)
0 
(0%)
I understand why I was invited to the TRUST Thyroid 
Trial
Intervention 
(n=38)
38 
(100%)
0 
(0%)
0 
(0%)
0.198
Control (n=31) 29 (93.5%)
2 
(6.5%)
0 
(0%)
I know why the medicine Levothyroxine is used to 
treat subclinical hypothyroidism
Intervention 
(n=38)
32 
(84.2%)
2 
(5.3%)
4 
(10.5%)
0.893
Control (n=31) 25 (80.6%)
3 
(9.7%)
3 
(9.7%)
I am aware of the side effects of Levothyroxine Intervention 
(n=38)
30 
(78.9%)
5 
(13.2%)
3 
(7.9%)
0.090
Control (n=31) 17 (54.8%)
7 
(22.6%)
7 
(22.6%)
I understand the impact of Levothyroxine on thyroid 
specific quality of life
Intervention 
(n=38)
31 
(81.6%)
5 
(13.2%)
2 
(5.3%)
0.281
Control (n=31) 20 (64.5%)
7 
(22.6%)
4 
(12.9%)
I understand how doctors will use the results of the 
TRUST Thyroid trial to treat people with subclinical 
hypothyroidism
Intervention 
(n=38)
33 
(86.8%)
2 
(5.3%)
3 
(7.9%)
0.878
Control (n=31) 26 (83.9%)
3 
(9.7%)
2 
(6.5%)
1Patient perceptions of understanding were assessed using a five point LIKERT scale.
Figure 1. Patient understanding of primary aim, side effect and trial result of the TRUST Thyroid Trial presented by group1.
1Patient understanding of primary aim, side effect and trial result was assessed using multiple choice questions.
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its usefulness as a measure of perceived understanding. The 
Kaiser-Meyer-Olkin (KMO) measure verified the sampling 
adequacy for the analysis, KMO= .83. Bartlett’s test of spheric-
ity indicated that the correlation matrix was significantly dif-
ferent from an identity matrix, X2 (.852) = 283.92, p<.001. An 
examination of eigenvalues greater than Kaiser’s criterion of 
one, suggested the extraction of one factor; this was supported 
by inspection of Cattell’s scree plot. An examination of the 
constituent items for this factor structure also indicated that items 
loaded most highly on a single factor. This single factor repre-
sents a measure of perceived understanding of trial results. PCA 
was then conducted using an oblique (direct oblimin) rotation, 
specifying the extraction of one factor. This model explained 
a combined 69.58% of the variance in patients understanding of 
the TRUST thyroid trial.
Cost of conducting PPI
The total cost of this study amounted to €8,049 (see Supplementary 
File 6: Costs of conducting PPI).
Discussion
While PPI is increasingly recognised as an important element 
of clinical research, evidence on optimal methods and potential 
impact is lacking4,9. Previous research conducted on the impact 
of PPI has largely focused on the experiences of participants 
and researchers25 and on the research process in broad terms26. 
In this study, our primary outcome was specific: a quantitative 
measure of patient understanding of trial results between those 
who received the patient-based approach and the standard 
approach. To our knowledge there has been no previous research 
conducted on the impact of PPI on patient understanding of trial 
results.
The involvement of clinical trial participants in this study offered 
insightful perspectives on the information needs of the study 
population in terms of receiving end of trial results. Study find-
ings show that trial participants want to receive the results of the 
clinical trial in which they had participated. This is supported 
by much of the available literature on patients’ preferences of 
receiving results, with up to 90% of participants in previous 
studies reporting a desire to receive results27. Focus group find-
ings showed that participants felt that receiving results would 
provide an acknowledgement of their individual contribution to 
the trial. This finding complements previous commentaries about 
result sharing being an ‘ethical imperative or ‘moral obligation’. 
Fernandez et al. points out that many participants place their trust 
in science and researchers owe a debt to participants to fulfil their 
trust and recognise their altruism12,28.
Unsurprisingly, findings also show that participants want to 
receive results that are accessible and easy to understand. In 
this study, the preferred format of receiving results was a letter 
posted to them directly from the TRUST trial. This preference 
is also consistent with the literature on patient preferences of 
receiving results. A previous study investigating prefrences of 
individuals taking part in a cardiac rehabilitation trial found 
that 80% of trial participants preferred to receive the results 
by post29. The patient-based approach identified in this study 
was feasible for researchers to develop with significant 
involvement from trial participants and adult literacy experts.
Previous studies exploring participants’ reactions found that 
sharing trial results with participants can cause some negative 
impacts such as anxiety, anger, guilt, upset and confusion30–32. 
As far as researchers in this study are aware, providing results 
did not cause any negative impacts. This may have been due 
to the fact that the TRUST trial had a low risk of morbidity or 
mortality compared to some of the other studies citing negative 
impacts. Both result methods contained the telephone number, 
email address and postal address of the research team and 
participants were urged to contact should they have any 
questions or concerns relating to the study. The research team 
did not receive any queries.
Previous systematic reviews highlight the lack of evidence on 
economic analysis of PPI and call for researchers to consider the 
costs of its implementation26,33. As discussed previously research 
funders are increasingly demanding that PPI be carried out in 
research. However, the costs of PPI are often underestimated 
and can cause a significant financial burden on research project 
budgets26,33–35. It is extremely important that researchers 
plan PPI at the grant proposal stage and estimate the costs 
appropriately. If these costs are not correctly estimated during 
the initial stages of developing research proposals, they may 
cause a financial burden on PPI partners.
Participants in this study were not paid for their time but were 
provided with a €20 voucher to cover travel expenses. When 
PPI is not the primary focus of a study, researchers do not 
consider the cost implications at the beginning of the study 
and are often tied with limited resources to carry out PPI34–36. 
INVOLVE, the national advisory group supporting active public 
involvement in health services, public health and social care 
research in the UK, have recommended that PPI partners should 
be paid for their involvement37. Despite this, existing research 
suggests that institutional difficulties make negotiating the 
mechanisms of paying participants very difficult34. One study 
reported that in order for participants to be remunerated for their 
efforts, they needed to be registered as employees, a process 
that incurred much paperwork and time delays34. This study out-
lines the cost of conducting PPI and includes a full breakdown 
of costs (see Supplementary File 6: Costs of conducting PPI). 
This breakdown provides a template to other researchers who 
plan to carry out and evaluate PPI as part of their research. It is 
important to note that not all costs associated with carrying out 
the study were included in this amount. For example, the only 
salary costed was that of the research assistant. The expertise 
provided by other members of the study team were not included 
in the total cost as they were being paid by the University 
or other research grants. The total cost of conducting this 
study was €8,049 which is not insignificant but should be 
considered in the context of the cost of large-scale trials.
Strengths and Limitations of the study
While this study provides important insights into patients’ prefer-
ences of receiving trial results, it is not without limitations. Firstly, 
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existing PPI literature states that ‘to understand the research 
needs and challenges, PPI has to engage people who are able to 
offer perspectives from the study population’3. All PPI partners 
in this study were active members of the research community 
as they had taken part in the TRUST trial and had agreed to 
long-term follow up. This is a strength of the SWAT as they were 
able to offer perspectives from the study population, however 
it does have an important implication for their reporting of 
understanding the results of the trial. They may be more 
inclined to rate their understanding as high because of their 
investment in the trial38, thus potentially minimising differences 
between the intervention and control conditions and minimising 
inferences that can be drawn about the intervention. Previous 
research suggests that people that actively choose to engage 
in research either as research participants or involvement part-
ners are more likely to be middle-class and highly educated39,40. 
In this study, those that attended the focus groups and PPI group 
were similar in education level to those that did not attend. 
This is not surprising considering the entire study sample 
had already actively volunteered to take part in the TRUST trial. 
Secondly, the results of the patient understanding question-
naire show that the levels of patient understanding were similar 
between the two groups. However, this study was underpowered 
to detect an effect. As this was a Study Within A Trial (SWAT), 
the power was limited by the sample size that was available to 
us from the trial (n=115). Furthermore, validation of the patient 
understanding questionnaire was limited by the sample size 
in this study. While validation of the questionnaire was 
limited, exploratory factor analysis provided some evidence that 
the questionnaire is a useful tool for measuring patient under-
standing of trial results. The developed questionnaire can be 
tailored for use in other trials in future examinations of patients 
understanding of trial results. This would provide insight into 
patient understanding and provide further validation data.
Thirdly, all SWATparticipants were aged 65 and over. The lay-
out, format and language of this patient-based approach which 
was identified and developed may only be relevant for this 
study population. Other trial populations may prefer to receive 
the results via email, online or in person from a member of the 
study team12. The evidence on patient preferences of receiving 
trial results is limited, therefore further research is needed to 
explore patient preferences of receiving trial results amongst 
different study populations.
It is also important to point out that the control group in this 
study received a copy of the trial results in a press release for-
mat. Most trial participants do not receive this. While this control 
method was a step further than normal procedure, the researchers 
in this study felt this was appropriate. The information pre-
sented in the press release was similar to that of the patient-based 
approach. However, the format and layout of the press release 
was different. Information was writtern in four long paragraphs 
separated by individual headings. It was also much shorter 
(1 page in total) that the patient-based approach (3 pages 
in total). Given the fact that press releases are written by 
public relations professionals with a view to communicating 
effectively and efficiently, this may have potentially minimised 
differences between the intervention and control conditions. The 
primary outcome of this study was assessing the impact of PPI 
on patient understanding of results, however, this was not 
the only potential impact. In hindsight, we adopted a limited 
approach to PPI in this study as we did not involve our PPI 
partners from the outset of the SWAT. Involving PPI partners in 
the development of core outcome sets for this SWAT could have 
identified other more appropriate primary outcome measures41.
The aim of this SWAT was to investigate methods of dissemi-
nating trial findings to trial participants by using a PPI approach 
to identify, develop and evaluate a patient-based method of 
receiving trial results. The PPI approach actively involved 
focus group participants in making decisions about the result 
method and worked with PPI partners to co-develop the 
result letter. However, PPI partners were not involved in other 
aspects of the research process such as research design, data 
collection or analysis. This is partly due to the fact that PPI is 
a relatively new concept in clinical trials. As the majority of 
the literature has only been published in the last 12 months, 
there is little evidence available on the impact of PPI and no gold 
standard or comprehensive guidelines for researchers to follow29. 
Thornton2 suggests that in order for PPI to develop it is impor-
tant to record its social and cultural history by collecting 
comprehensive databases and undertaking ongoing reviews of 
the impact of PPI. This paper along with the study protocol have 
been written in adherence with the Guidelines for Reporting 
Involvement of Patients and the Public23, thus providing tem-
plates for involving patients and the public in clinical trial design 
and development. This study is an important step forwards 
in documenting the process of conducting PPI as part of a SWAT 
and evaluating its impact. Future research is needed to further 
develop PPI in clinical trial settings. As there is currently 
no gold standard or comprehensive guidelines for researchers 
to follow when evaluating the impact of PPI, further research is 
needed. This research should involve PPI partners in the devel-
opment of core outcome sets for evaluating PPI impact. These 
would significantly enhance the literature in the area.
Conclusion
Patient and Public Involvement (PPI) is advocated for every step 
of the trial process. We have demonstrated that it is feasible to 
involve PPI partners in the development of dissemination mate-
rials. Sharing clinical trial results with participants in a format 
understandable to laypersons will soon be a legal requirement11. 
However, there is a significant lack of evidence as to the most 
appropriate methods of sharing results with participants. The study 
identified and developed a patient-based approach to disseminat-
ing clinical trial results for trial participants. Although, in this 
study PPI did not influence patients’ final understanding of results, 
it documents the process of conducting PPI within the clinical 
trial setting. This process may be useful for other trialists inter-
ested in conducting and evaluating the impact of PPI in clinical 
trials.
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The research was approved in Ireland by the Clinical Research 
Ethics Committee of the Cork Teaching Hospitals, UCC, Ref 
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All participants provided signed informed consent to take part 
in the study.
Data availability
The raw data from this study cannot be sufficiently de-identified, 
and therefore are not publicly available. However, the data from 
the current study are available for further (collaborative) research 
purposes on reasonable request. Available datasets include 
transcripts from focus groups, field notes from PPI sessions 
and responses from the patient understanding questionnaire. 
To access the data, please contact the corresponding author 
(emmy.racine@ucc.ie) or the Principal Investigator (patricia. 
kearney@ucc.ie). Researchers must provide a written proposal 
on how the data will be used in research before access is 
granted.
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Marina Zaki   
UCD School of Nursing, Midwifery and Health Systems, University College Dublin, Dublin, Ireland 
The paper is an important contribution to enhance patient and public involvement in trial 
research. A very worthy SWAT, one of a few SWATs conducted within the TRUST trial. Please 
explain SWAT at the outset. 
  
Some suggestions: 
  
While the authors refer to the PPI definition by INVOLVE it would have been helpful to get a 
clearer understanding of the authors’ specific understanding and conceptualisation of PPI in the 
context of their study. The approach of involving patients in shaping the dissemination of results is 
laudable but admittedly quite limiting and appears to be an afterthought rather than an integral 
element of the trial. The paper very much resides in the traditional experimental (albeit using a 
preference-based design), researcher-led paradigm (clearly expressed in the ‘randomisation’ to 
determine effectiveness of modes of dissemination – which somewhat contravenes the notion of 
engaging with a diverse public and patient population for bespoke dissemination) with limited 
shift of control over the research process to patients or the public. For example, how were study 
participants involved at the intersection of analysis, dissemination and knowledge transfer 
(selection of outcomes that are relevant? Decision on subgroup analysis? Involvement in 
interpretation of analysis findings? Decisions about outlets for dissemination (audiences, events, 
settings, format and content?). 
  
It would be helpful to see a more detailed description of the PPI Group. How was this group 
selected, what is its composition, how frequently did it meet and what was its immediate influence 
in the research process throughout. Did members of the PPI group participate as co-researchers 
at any stage of contribute to the facilitation, analysis etc of the focus group results? 
 
Paper mentions qualitative aspect and discusses the need to ensure accurate and relevant 
information is being shared with participants. Wonder if benefit could be derived from drawing 
upon the notion of “translational statistics”, where additional statistical information is obtained, 
analysed and accurately translated to clinically meaningful findings - perhaps with the authors 
referring to the tension of statistical significance versus clinical relevance and the importance of 
minimising statistical jargon when presenting trial results. Great to see contribution of NALA – but 
did the authors experience this barrier of translating statistical results into findings that were 
clinically relevant, most notably in the context of PPI in understanding this? The suggestion 
therefore is that including PPI here helps to minimise both statistical and clinical jargon, which can 
often be challenging, for a concise and accurate report. 
  
Also, some of the language used appears to be a departure from the PPI approach. For example 
(in Section Phase 3), “This document highlights the information that trial participants should 
understand after reading their trial summary.” The intention of the authors is clear but the 
wording very much suggests a prescriptive approach on the part of the academic team. 
  
It would be important to distinguish between ‘literacy’ and ‘health literacy’. They represent related 
but substantially different concepts. 
  
In line with other members of the trial community, the paper could benefit from the word 
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‘transparency’ – paragraph 2 introduction – to put it in context with other papers discussing 
sharing of trial findings and results. The authors could also consider making reference to the 
AllTrials initiative in paragraph 2 (not directly relevant to PPI, but important nonetheless in the 
movement towards transparency in trials). 
  
It would be helpful to clarify how the CODM was specifically used in the process and to provide 
evidence for the step by step approach. 
  
Methods section of Phase 2 - “ One member of the research team was un-blinded in order to 
perform the randomisation and distribute the results of the trial.” – what other parts of the study 
was this member involved in? Did their unblinding have any impact on any other aspects of the 
study? 
  
The paper could benefit from briefly mentioning the ‘moral obligation’ trialists have to share 
results – in this sense, I mean results to be the trial findings – (results in the context of data 
sharing is subject to new EU GDPR, which is something the authors could consider to mention but 
unlikely to have a place for discussion in this article; justification for not being able to share the 
data is already briefly mentioned in the “data availability” paragraph). So the term ‘moral 
obligation’ of trialists would complement the qualitative quotes the authors have in the results 
section about patients feeling they contributed to research. 
  
Phase 1 results part: “This feeling of contributing for a collective benefit was further reinforced 
when participants discussed their desire to understand how the results of the trial will be 
implemented by medical experts and ultimately how it will affect others who have the condition:” à 
could mention one aspect, particularly this being a drug trial, of how statistics can explain why one 
treatment works on some patients and not others etc and that this may be something public and 
patients would like to know, therefore is important to accurately portray. 
  
“education” – demographic not discussed in detail in other sections of paper- only mentioned in 
terms of not being statistically significantly different – need more? Relevance to PPI is not 
explained thoroughly and should be strengthened 
 
Great mention of CT regulation and checklist when reporting PPI – but could also benefit from 
mentioning the fundamental reporting guidance in trials, such as putting SPIRIT into context and 
relevance, if any, to layman’s terms and similar to using CONSORT as a reference and explaining 
this to PPI? Also refer to www.clinicaltrials.gov reporting section for public 
  
Clearly, it is a strength of the SWAT having participants already from the trial - see the trial 
through from beginning to end so their help is important in terms of accurate 
context/background when interpreting and disseminating findings 
  
Generally, well-written, well laid out, concise and important paper.
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
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Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Yes
If applicable, is the statistical analysis and its interpretation appropriate?
I cannot comment. A qualified statistician is required.
Are all the source data underlying the results available to ensure full reproducibility?
No source data required
Are the conclusions drawn adequately supported by the results?
Partly
Competing Interests: No competing interests were disclosed.
We confirm that we have read this submission and believe that we have an appropriate level 
of expertise to confirm that it is of an acceptable scientific standard.
Author Response 11 Jan 2019
Emmy Racine, University College Cork, Cork, Ireland 
The paper is an important contribution to enhance patient and public involvement in 
trial research. A very worthy SWAT, one of a few SWATs conducted within the TRUST 
trial. Please explain SWAT at the outset. 
 
Firstly, thank you for your comprehensive comments.  
 
To address this, we have inserted the following sentence into the abstract:  
“The aim of this Study Within A Trial (SWAT) is to use….” (Abstract) 
 
 
While the authors refer to the PPI definition by INVOLVE it would have been helpful to 
get a clearer understanding of the authors’ specific understanding and 
conceptualisation of PPI in the context of their study. The approach of involving 
patients in shaping the dissemination of results is laudable but admittedly quite 
limiting and appears to be an afterthought rather than an integral element of the 
trial. The paper very much resides in the traditional experimental (albeit using a 
preference-based design), researcher-led paradigm (clearly expressed in the 
‘randomisation’ to determine effectiveness of modes of dissemination – which 
somewhat contravenes the notion of engaging with a diverse public and patient 
population for bespoke dissemination) with limited shift of control over the research 
process to patients or the public. For example, how were study participants involved 
at the intersection of analysis, dissemination and knowledge transfer (selection of 
outcomes that are relevant? Decision on subgroup analysis? Involvement in 
interpretation of analysis findings? Decisions about outlets for dissemination 
(audiences, events, settings, format and content?). 
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We have reflected on our approach to PPI in this Study Within a Trial and have added the 
following text to the manuscript to address this comment: 
 
The aim of this SWAT was to investigate methods of disseminating trial findings to trial 
participants by using a PPI approach to identify, develop and evaluate a patient-based 
method of receiving trial results. The PPI approach actively involved focus group 
participants in making decisions about the result method and working with PPI partners to 
co-develop the result letter. However, PPI partners were not involved in other aspects of the 
research process such as research design, data collection or analysis. This is partly due to 
the fact that PPI is a relatively new concept in clinical trials. As the majority of the literature 
has only been published in the last 12 months, there is little evidence available on the 
impact of PPI and no gold standard or comprehensive guidelines for researchers to follow 
(30). (Discussion: Strengths and Limitations, Paragraph 5) 
 
It would be helpful to see a more detailed description of the PPI Group. How was this 
group selected, what is its composition, how frequently did it meet and what was its 
immediate influence in the research process throughout. Did members of the PPI 
group participate as co-researchers at any stage of contribute to the facilitation, 
analysis etc of the focus group results? 
 
A more detailed description of the PPI group has been added to the manuscript to address 
this comment: 
 
A PPI group was established to develop and refine the content of the patient-based 
approach for the dissemination of results. During the focus groups, three TRUST trial 
participants volunteered to take part in the PPI group. In addition to these three PPI 
partners, an additional partner was identified from a previous qualitative research study 
undertaken by the research team. This individual was keen to learn more about research 
and expressed an interested in being involved in future projects. While this individual had 
previous experience of taking part in research (as an interview participant), she had no 
experience of taking part in a clinical trial or being involved as a PPI partner.(Methods: PPI 
group) 
 
There were four. PPI partners in total (three trial participants and one older adult).  Each 
partner took part in one one-to-one session (Results: PPI group) 
 
Members of the PPI group did not participate as co-researchers in the facilitation, analysis 
etc. of focus group results.  We have addressed our approach to PPI in the previous 
comment and have made necessary additions to the main manuscript.  
 
Paper mentions qualitative aspect and discusses the need to ensure accurate and 
relevant information is being shared with participants. Wonder if benefit could be 
derived from drawing upon the notion of “translational statistics”, where additional 
statistical information is obtained, analysed and accurately translated to clinically 
meaningful findings - perhaps with the authors referring to the tension of statistical 
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significance versus clinical relevance and the importance of minimising statistical 
jargon when presenting trial results. Great to see contribution of NALA – but did the 
authors experience this barrier of translating statistical results into findings that 
were clinically relevant, most notably in the context of PPI in understanding this? The 
suggestion therefore is that including PPI here helps to minimise both statistical and 
clinical jargon, which can often be challenging, for a concise and accurate report. 
 
While we believe this is an important point, we believe it was not a major contributor in our 
study. As there were no statistically significant or clinically relevant results, the results of the 
trial were simple and straightforward (ie. no effect), and so we did not have this challenge. 
 
 
Also, some of the language used appears to be a departure from the PPI approach. For 
example (in Section Phase 3), “This document highlights the information that trial 
participants should understand after reading their trial summary.” The intention of 
the authors is clear but the wording very much suggests a prescriptive approach on 
the part of the academic team. 
 
The authors do not mean to sound prescriptive in their approach. This sentence has been 
changed to the following: 
 
‘This document highlights the information which should be presented to trial participants in 
the trial summary at the end of a trial’. (Methods: Evaluation) 
 
It would be important to distinguish between ‘literacy’ and ‘health literacy’. They 
represent related but substantially different concepts. 
 
Both concepts were important in this study. We collaborated with the National Adult 
Literacy Agency to ensure that the material in the results letter to trial participants was 
sufficiently easy to read and understand (literacy). This would help to ensure that trial 
participants were able to make sound health decisions based on the information presented 
to them (health literacy).  
 
To ensure accuracy, we have changed the wording throughout the document to ‘adult 
literacy’ and described our approach as follows:  
 
Adult literacy review 
While the PPI group had significant input into the format and language used in the patient-
based approach. The research team felt that it would be of additional benefit to collaborate 
with the National Adult Literacy Agency (NALA) to ensure the document adhered to national 
“Plain English” standards. These standards ensured that the information presented to trial 
participants was sufficiently easy to read and understand (literacy). This would help to 
ensure that trial participants were able to make sound health decisions based on the 
information presented (health literacy) (15). This review was an iterative process with 
several drafts exchanged for editing. (L-P-)  
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In line with other members of the trial community, the paper could benefit from the 
word ‘transparency’ – paragraph 2 introduction – to put it     in context with other 
papers discussing sharing of trial findings and results. The authors could also consider 
making reference to the AllTrials initiative in paragraph 2 (not directly relevant to PPI, 
but important nonetheless in the movement towards transparency in trials). 
 
Yes we agree, this paragraph would benefit from a reference to the recent movement 
towards transparency in trials. The following text has been added:  
 
The increasing understanding of the importance of sharing research results with study 
participants is somewhat linked to a wider movement towards transparency in trials. This 
movement is largely promoted by initiatives such as SPIRIT, CONSORT and AllTrials. The 
SPIRIT Statement provides guidance to researchers to improve the completeness and 
quality of trial protocols (11), the  Consolidated Standards of Reporting Trials (CONSORT) 
Statement is an evidence based, minimum set of recommendations for reporting 
randomised trials (12) and the  AllTrials initiative calls for all past and present trials to be 
registered and their full methods and summary results reported (13). Some of these 
initiatives also include recommendations for disseminating results to research participants. 
For example, the SPIRIT statement states that study results must be released to 
participating physicians, referring physicians, patients and the general medical community 
(11). (Introduction, Paragraph 2). 
 
It would be helpful to clarify how the CODM was specifically used in the process and to 
provide evidence for the step by step approach. 
 
The following text has been added to the manuscript to describe how the CODM model was 
specifically used in this study: 
 
The Consensus-Oriented-Decision-Making (CODM) model was used to guide the group to 
reach a consensus. The CODM model is accepted as a flexible model for reaching decisions 
 (14). In this study some of the steps were initiated by the focus group facilitator and others 
occurred naturally as a follow on from the previous step. Below is an outline of each of the 
seven steps of the CODM model and how they were used in this study: 
1.    Framing the topic: The focus group facilitator introduced the idea of sharing results with 
participants and provided some context on the reasons why results are/ are not shared with 
participants. 
2.    Open discussion: The facilitator asked the group whether or not they think results 
should be shared with trial participants and whether or not they would like to receive the 
results of the TRUST trial.  
3.    Identifying underlying concerns: The previous discussion naturally followed on to 
participants asking questions and expressing concerns about the result method, content 
and language that would be used.  
4.    Collaborative proposal building: The group worked together to agree on the important 
elements of the results in terms of result method, content and language. 
5.    Choosing a direction: This step occurred naturally as part of the previous step.  
6.    Synthesizing a final proposal: The facilitator re-iterated the proposal the group had 
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agreed upon and asked the group for feedback. 
7.    Closure: This step occurred naturally as part of the previous step. (Methods: Phase 1) 
 
Methods section of Phase 2 - “ One member of the research team was un-blinded in 
order to perform the randomisation and distribute the results of the trial.” – what 
other parts of the study was this member involved in? Did their unblinding have any 
impact on any other aspects of the study? 
 
This member of the research team (AC) was involved in the design of the study, preparing 
study materials, performing data collection and developing the result material. After they 
were un-blinded in order to perform the randomisation and distribute the results, they were 
not involved in the data analysis or interpretation in any way. The following sentence has 
been added to the manuscript to provide clarity on this: 
 
“As they were un-blinded to perform these two important tasks, they were not involved in 
the data analysis or interpretation in any way.” (Methods: Phase 2) 
 
The paper could benefit from briefly mentioning the ‘moral obligation’ trialists have to 
share results – in this sense, I mean results to be the trial findings – (results in the 
context of data sharing is subject to new EU GDPR, which is something the authors 
could consider to mention but unlikely to have a place for discussion in this article; 
justification for not being able to share the data is already briefly mentioned in the 
“data availability” paragraph). So the term ‘moral obligation’ of trialists would 
complement the qualitative quotes the authors have in the results section about 
patients feeling they contributed to research. 
 
We have inserted the following text into the discussion to address this: 
 
“Focus group findings showed that participants felt that receiving results would provide an 
acknowledgement of their individual contribution to the trial. This finding complements 
previous commentaries about result sharing being an ‘ethical imperative or ‘moral 
obligation’. Fernandez et al. points out that many participants place their trust in science 
and researchers owe a debt to participants to fulfil their trust and recognise their altruism 
(10, 23).” (Discussion, Paragraph 2) 
 
We have not mentioned the EU GDPR in this paper as we feel it is not directly relevant to 
sharing trial results with participants. The upcoming EU Clinical Trial regulation is 
mentioned in the introduction which will be the main EU regulation which requires 
investigators to share clinical trial results with participants in a format understandable to 
laypersons.  
 
Phase 1 results part: “This feeling of contributing for a collective benefit was further 
reinforced when participants discussed their desire to understand how the results of 
the trial will be implemented by medical experts and ultimately how it will affect 
others who have the condition:” à could mention one aspect, particularly this being a 
drug trial, of how statistics can explain why one treatment works on some patients 
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and not others etc and that this may be something public and patients would like to 
know, therefore is important to accurately portray. 
 
We acknowledge that understanding how statistics can explain why one treatment works on 
some patients and not others is an important aspect and may be something that patients 
would like to know. However, this aspect was not brought up by the trial participants in this 
study (either during the focus groups or PPI sessions). As this paper was about listening to 
trial participants and giving them the information they wanted to know, we feel it would be 
inappropriate to add it in to the paper at this late stage and presume that it is something 
that they wanted to know.  Therefore, while it is an important aspect, we have not made any 
changes to address it in our paper. 
 
“education” – demographic not discussed in detail in other sections of paper- only 
mentioned in terms of not being statistically significantly different – need more? 
Relevance to PPI is not explained thoroughly and should be strengthened 
 
We have added the following text to the discussion to address this:  
 
Previous research suggests that people that actively choose to engage in research either as 
research participants or involvement partners are more likely to be middle-class and highly 
educated (34, 35). In this study, those that attended the focus groups and PPI group were 
similar in education level to those that did not attend. This is not surprising considering the 
entire study sample had already actively volunteered to take part in the TRUST trial. 
 (Discussion: Strengths and Limitations, Paragraph 1) 
 
Great mention of CT regulation and checklist when reporting PPI – but could also 
benefit from mentioning the fundamental reporting guidance in trials, such as 
putting SPIRIT into context and relevance, if any, to layman’s terms and similar to 
using CONSORT as a reference and explaining this to PPI? Also refer to reporting 
section for public 
 
The following text has been inserted into the introduction to address this comment: 
 
The increasing understanding of the importance of sharing research results with study 
participants is somewhat linked to a wider movement towards transparency in trials. This 
movement is largely promoted by initiatives such as SPIRIT, CONSORT and AllTrials. The 
SPIRIT Statement provides guidance to researchers to improve the completeness and 
quality of trial protocols (11), the  Consolidated Standards of Reporting Trials (CONSORT) 
Statement is an evidence based, minimum set of recommendations for reporting 
randomised trials (12) and the  AllTrials initiative calls for all past and present trials to be 
registered and their full methods and summary results reported (13). Some of these 
initiatives also include recommendations for disseminating results to research participants. 
For example, the SPIRIT statement states that study results must be released to 
participating physicians, referring physicians, patients and the general medical community 
(11). (Introduction, Paragraph 2) 
 
HRB Open Research
 
Page 21 of 43
HRB Open Research 2019, 1:14 Last updated: 10 SEP 2020
Clearly, it is a strength of the SWAT having participants already from the trial - see the 
trial through from beginning to end so their help is important in terms of accurate 
context/background when interpreting and disseminating findings 
 
We have made the following changes to the manuscript to address this: 
 
This section of the discussion has been reworded from ‘Limitations of the study’ to 
‘Strengths and limitations of the study’ (Discussion) 
 
This paragraph in question has been rephrased as a highlight of the SWAT and moved to 
the first paragraph in the ‘Strengths and limitations of the study’ section. It now reads as 
following: 
 
“While this study has provided important insights into patients’ preferences of receiving trial 
results, it is not without limitations. Firstly, existing PPI literature states that ‘to understand 
the research needs and challenges, PPI has to engage people who are able to offer 
perspectives from the study population’ (3). All PPI partners in this study were active 
members of the research community as they had taken part in the TRUST trial and had 
agreed for long-term follow up. This is a major strength of the SWAT as they were able to 
offer perspectives from the study population, however it does have an important 
implication for their reporting of understanding the results of the trial. They may be more 
inclined to rate their understanding as high because of their investment in the trial (31), 
thus potentially minimising differences between the intervention and control conditions 
and minimising inferences that can be drawn about the intervention.”  Discussion: 
Strengths and Limitations, Paragraph 1) 
 
Generally, well-written, well laid out, concise and important paper.  
Competing Interests: No competing interests were disclosed.
Author Response 11 Jan 2019
Emmy Racine, University College Cork, Cork, Ireland 
The paper is an important contribution to enhance patient and public involvement in 
trial research. A very worthy SWAT, one of a few SWATs conducted within the TRUST 
trial. Please explain SWAT at the outset. 
  
Firstly, thank you for your comprehensive comments. 
 
To address this, we have inserted the following sentence into the abstract: 
“The aim of this Study Within A Trial (SWAT) is to use….” (Abstract) 
  
  
While the authors refer to the PPI definition by INVOLVE it would have been helpful to 
get a clearer understanding of the authors’ specific understanding and 
conceptualisation of PPI in the context of their study. The approach of involving 
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patients in shaping the dissemination of results is laudable but admittedly quite 
limiting and appears to be an afterthought rather than an integral element of the 
trial. The paper very much resides in the traditional experimental (albeit using a 
preference-based design), researcher-led paradigm (clearly expressed in the 
‘randomisation’ to determine effectiveness of modes of dissemination – which 
somewhat contravenes the notion of engaging with a diverse public and patient 
population for bespoke dissemination) with limited shift of control over the research 
process to patients or the public. For example, how were study participants involved 
at the intersection of analysis, dissemination and knowledge transfer (selection of 
outcomes that are relevant? Decision on subgroup analysis? Involvement in 
interpretation of analysis findings? Decisions about outlets for dissemination 
(audiences, events, settings, format and content?). 
 
We agree that our approach to PPI in this study was limited. We involved trial participants in 
shaping the dissemination of results and did not involve them in other stages of the 
research process. We agree that there was a limited shift of control over the research 
process to PPI partners. We have reflected on our limited approach to PPI and have added 
the following text to the manuscript to address this comment: 
 
The aim of this SWAT was to investigate methods of disseminating trial findings to trial 
participants by using a PPI approach to identify, develop and evaluate a patient-based 
method of receiving trial results. The PPI approach actively involved focus group 
participants in making decisions about the result method and working with PPI partners to 
co-develop the result letter. However, PPI partners were not involved in other aspects of the 
research process such as research design, data collection or analysis. This is partly due to 
the fact that PPI is a relatively new concept in clinical trials. As the majority of the literature 
has only been published in the last 12 months, there is little evidence available on the 
impact of PPI and no gold standard or comprehensive guidelines for researchers to follow 
(30). (Discussion: Strengths and Limitations, Paragraph 5) 
 
This study is an important step forwards in documenting the process of conducting PPI as 
part of a SWAT and evaluating its impact. (Discussion: Strengths and Limitations, Paragraph 
5) 
  
It would be helpful to see a more detailed description of the PPI Group. How was this 
group selected, what is its composition, how frequently did it meet and what was its 
immediate influence in the research process throughout. Did members of the PPI 
group participate as co-researchers at any stage of contribute to the facilitation, 
analysis etc of the focus group results? 
 
A more detailed description of the PPI group has been added to the manuscript to address 
this comment: 
  
A PPI group was established to develop and refine the content of the patient-based 
approach for the dissemination of results. During the focus groups, three TRUST trial 
participants volunteered to take part in the PPI group. In addition to these three PPI 
partners, an additional partner was identified from a previous qualitative research study 
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undertaken by the research team. This individual was keen to learn more about research 
and expressed an interested in being involved in future projects. While this individual had 
previous experience of taking part in research (as an interview participant), she had no 
experience of taking part in a clinical trial or being involved as a PPI partner. (Methods: PPI 
group). 
 
There were four. PPI partners in total (three trial participants and one older adult). Each 
partner took part in one one-to-one session (Results: PPI group). 
  
Members of the PPI group did not participate as co-researchers in the facilitation, analysis 
etc. of focus group results.  We have addressed our limited approach to PPI in the previous 
comment and have made necessary additions to the main manuscript. 
  
Paper mentions qualitative aspect and discusses the need to ensure accurate and 
relevant information is being shared with participants. Wonder if benefit could be 
derived from drawing upon the notion of “translational statistics”, where additional 
statistical information is obtained, analysed and accurately translated to clinically 
meaningful findings - perhaps with the authors referring to the tension of statistical 
significance versus clinical relevance and the importance of minimising statistical 
jargon when presenting trial results. Great to see contribution of NALA – but did the 
authors experience this barrier of translating statistical results into findings that 
were clinically relevant, most notably in the context of PPI in understanding this? The 
suggestion therefore is that including PPI here helps to minimise both statistical and 
clinical jargon, which can often be challenging, for a concise and accurate report. 
  
While we believe this is an important point, we believe it was not a major contributor in our 
study. As there were no statistically significant or clinically relevant results, the results of the 
trial were simple and straightforward (ie. no effect), and so we did not have this challenge. 
  
  
Also, some of the language used appears to be a departure from the PPI approach. For 
example (in Section Phase 3), “This document highlights the information that trial 
participants should understand after reading their trial summary.” The intention of 
the authors is clear but the wording very much suggests a prescriptive approach on 
the part of the academic team. 
  
The authors do not mean to sound prescriptive in their approach. This sentence has been 
changed to the following: 
 
‘This document highlights the information which should be presented to trial participants in 
the trial summary at the end of a trial’. (Methods: Evaluation) 
  
It would be important to distinguish between ‘literacy’ and ‘health literacy’. They 
represent related but substantially different concepts. 
 
Both concepts were important in this study. We collaborated with the National Adult 
Literacy Agency to ensure that the material in the results letter to trial participants was 
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sufficiently easy to read and understand (literacy). This would help to ensure that trial 
participants were able to make sound health decisions based on the information presented 
to them (health literacy). 
 
To ensure accuracy, we have changed the wording throughout the document to ‘adult 
literacy’ and described our approach as follows: 
 
Adult literacy review 
While the PPI group had significant input into the format and language used in the patient-
based approach. The research team felt that it would be of additional benefit to collaborate 
with the National Adult Literacy Agency (NALA) to ensure the document adhered to national 
“Plain English” standards. These standards ensured that the information presented to trial 
participants was sufficiently easy to read and understand (literacy). This would help to 
ensure that trial participants were able to make sound health decisions based on the 
information presented (health literacy) (15). This review was an iterative process with 
several drafts exchanged for editing. 
 
In line with other members of the trial community, the paper could benefit from the 
word ‘transparency’ – paragraph 2 introduction – to put it           in context with other 
papers discussing sharing of trial findings and results. The authors could also consider 
making reference to the AllTrials initiative in paragraph 2 (not directly relevant to PPI, 
but important nonetheless in the movement towards transparency in trials). 
 
Yes we agree, this paragraph would benefit from a reference to the recent movement 
towards transparency in trials. The following text has been added: 
 
The increasing understanding of the importance of sharing research results with study 
participants is somewhat linked to a wider movement towards transparency in trials. This 
movement is largely promoted by initiatives such as SPIRIT, CONSORT and AllTrials. The 
SPIRIT Statement provides guidance to researchers to improve the completeness and 
quality of trial protocols (11), the  Consolidated Standards of Reporting Trials (CONSORT) 
Statement is an evidence based, minimum set of recommendations for reporting 
randomised trials (12) and the  AllTrials initiative calls for all past and present trials to be 
registered and their full methods and summary results reported (13). Some of these 
initiatives also include recommendations for disseminating results to research participants. 
For example, the SPIRIT statement states that study results must be released to 
participating physicians, referring physicians, patients and the general medical community 
(11). (Introduction, Paragraph 2). 
  
It would be helpful to clarify how the CODM was specifically used in the process and to 
provide evidence for the step by step approach. 
 
The following text has been added to the manuscript to describe how the CODM model was 
specifically used in this study: 
 
The Consensus-Oriented-Decision-Making (CODM) model was used to guide the group to 
reach a consensus. The CODM model is accepted as a flexible model for reaching decisions  
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(14). In this study some of the steps were initiated by the focus group facilitator and others 
occurred naturally as a follow on from the previous step. Below is an outline of each of the 
seven steps of the CODM model and how they were used in this study:
Framing the topic: The focus group facilitator introduced the idea of sharing results 
with participants and provided some context on the reasons why results are/ are not 
shared with participants.
1. 
Open discussion: The facilitator asked the group whether or not they think results 
should be shared with trial participants and whether or not they would like to receive 
the results of the TRUST trial.
2. 
Identifying underlying concerns: The previous discussion naturally followed on to 
participants asking questions and expressing concerns about the result method, 
content and language that would be used.
3. 
Collaborative proposal building: The group worked together to agree on the 
important elements of the results in terms of result method, content and language.
4. 
Choosing a direction: This step occurred naturally as part of the previous step.5. 
Synthesizing a final proposal: The facilitator re-iterated the proposal the group had 
agreed upon and asked the group for feedback.
6. 
Closure: This step occurred naturally as part of the previous step. (Methods: Phase 1)7. 
  
Methods section of Phase 2 - “ One member of the research team was un-blinded in 
order to perform the randomisation and distribute the results of the trial.” – what 
other parts of the study was this member involved in? Did their unblinding have any 
impact on any other aspects of the study? 
 
This member of the research team (AC) was involved in the design of the study, preparing 
study materials, performing data collection and developing the result material. After they 
were un-blinded in order to perform the randomisation and distribute the results, they were 
not involved in the data analysis or interpretation in any way. The following sentence has 
been added to the manuscript to provide clarity on this: 
 
“As they were un-blinded to perform these two important tasks, they were not involved in 
the data analysis or interpretation in any way.” (Methods: Phase 2) 
  
The paper could benefit from briefly mentioning the ‘moral obligation’ trialists have to 
share results – in this sense, I mean results to be the trial findings – (results in the 
context of data sharing is subject to new EU GDPR, which is something the authors 
could consider to mention but unlikely to have a place for discussion in this article; 
justification for not being able to share the data is already briefly mentioned in the 
“data availability” paragraph). So the term ‘moral obligation’ of trialists would 
complement the qualitative quotes the authors have in the results section about 
patients feeling they contributed to research. 
 
We have inserted the following text into the discussion to address this: 
 
“Focus group findings showed that participants felt that receiving results would provide an 
acknowledgement of their individual contribution to the trial. This finding complements 
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previous commentaries about result sharing being an ‘ethical imperative or ‘moral 
obligation’. Fernandez et al. points out that many participants place their trust in science 
and researchers owe a debt to participants to fulfil their trust and recognise their altruism 
(10, 23).” (Discussion, Paragraph 2) 
 
We have not mentioned the EU GDPR in this paper as we feel it is not directly relevant to 
sharing trial results with participants. The upcoming EU Clinical Trial regulation is 
mentioned in the introduction which will be the main EU regulation which requires 
investigators to share clinical trial results with participants in a format understandable to 
laypersons. 
 
Phase 1 results part: “This feeling of contributing for a collective benefit was further 
reinforced when participants discussed their desire to understand how the results of 
the trial will be implemented by medical experts and ultimately how it will affect 
others who have the condition:” à could mention one aspect, particularly this being a 
drug trial, of how statistics can explain why one treatment works on some patients 
and not others etc and that this may be something public and patients would like to 
know, therefore is important to accurately portray. 
 
We acknowledge that understanding how statistics can explain why one treatment works on 
some patients and not others is an important aspect and may be something that patients 
would like to know. However, this aspect was not brought up by the trial participants in this 
study (either during the focus groups or PPI sessions). As this paper was about listening to 
trial participants and giving them the information they wanted to know, we feel it would be 
inappropriate to add it in to the paper at this late stage and presume that it is something 
that they wanted to know.  Therefore, while it is an important aspect, we have not made any 
changes to address it in our paper. 
 
“education” – demographic not discussed in detail in other sections of paper- only 
mentioned in terms of not being statistically significantly different – need more? 
Relevance to PPI is not explained thoroughly and should be strengthened 
 
We have added the following text to the discussion to address this: 
 
Previous research suggests that people that actively choose to engage in research either as 
research participants or involvement partners are more likely to be middle-class and highly 
educated (34, 35). In this study, those that attended the focus groups and PPI group were 
similar in education level to those that did not attend. This is not surprising considering the 
entire study sample had already actively volunteered to take part in the TRUST trial.  
(Discussion: Strengths and Limitations, Paragraph 1) 
 
Great mention of CT regulation and checklist when reporting PPI – but could also 
benefit from mentioning the fundamental reporting guidance in trials, such as 
putting SPIRIT into context and relevance, if any, to layman’s terms and similar to 
using CONSORT as a reference and explaining this to PPI? Also refer to reporting 
section for public 
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The following text has been inserted into the introduction to address this comment: 
 
The increasing understanding of the importance of sharing research results with study 
participants is somewhat linked to a wider movement towards transparency in trials. This 
movement is largely promoted by initiatives such as SPIRIT, CONSORT and AllTrials. The 
SPIRIT Statement provides guidance to researchers to improve the completeness and 
quality of trial protocols (11), the  Consolidated Standards of Reporting Trials (CONSORT) 
Statement is an evidence based, minimum set of recommendations for reporting 
randomised trials (12) and the  AllTrials initiative calls for all past and present trials to be 
registered and their full methods and summary results reported (13). Some of these 
initiatives also include recommendations for disseminating results to research participants. 
For example, the SPIRIT statement states that study results must be released to 
participating physicians, referring physicians, patients and the general medical community 
(11). (Introduction, Paragraph 2) 
 
Clearly, it is a strength of the SWAT having participants already from the trial - see the 
trial through from beginning to end so their help is important in terms of accurate 
context/background when interpreting and disseminating findings 
 
We have made the following changes to the manuscript to address this: 
 
This section of the discussion has been reworded from ‘Limitations of the study’ to 
‘Strengths and limitations of the study’ (Discussion) 
  
This paragraph in question has been rephrased as a highlight of the SWAT and moved to 
the first paragraph in the ‘Strengths and limitations of the study’ section. It now reads as 
following: 
 
“While this study has provided important insights into patients’ preferences of receiving trial 
results, it is not without limitations. Firstly, existing PPI literature states that ‘to understand 
the research needs and challenges, PPI has to engage people who are able to offer 
perspectives from the study population’ (3). All PPI partners in this study were active 
members of the research community as they had taken part in the TRUST trial and had 
agreed for long-term follow up. This is a major strength of the SWAT as they were able to 
offer perspectives from the study population, however it does have an important 
implication for their reporting of understanding the results of the trial. They may be more 
inclined to rate their understanding as high because of their investment in the trial (31), 
thus potentially minimising differences between the intervention and control conditions 
and minimising inferences that can be drawn about the intervention.”  Discussion: 
Strengths and Limitations, Paragraph 1) 
  
Generally, well-written, well laid out, concise and important paper.  
Competing Interests: No competing interests were disclosed.
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This research article reports a Study Within A Trial (SWAT) hosted by the Thyroid Hormone 
Replacement for Subclinical Hypo-Thyroidism Trial (TRUST). The TRUST trial is an international trial 
and the SWAT was only conducted in one of the participating countries, namely Ireland. The 
purpose of the SWAT was to use a ‘Patient and Public Involvement (PPI) approach’ to identify and 
develop results reporting for the TRUST trial to its participants and subsequently evaluate the 
result materials. Evaluation of the result materials was carried out by assessing recipients’ 
understanding of the trial results compared to result materials as provided by the lead TRUST site. 
The SWAT protocol was published last year. 
  
Although the study is small and has some limitations it is an important piece in the result 
provision literature for trials, providing the detailed account of a thorough approach to the results 
provision process in trials. 
  
We have a few comments which should be addressed: 
  
Overall  
Some people wonder why it is necessary to quantify at all the contribution public and patients 
make to a trial given that they are clearly trial stakeholders and we don’t do this for other 
stakeholders such as the statistician and the trial manager. Other people definitely do think it is 
necessary to quantify the gain from PPI. It would be good if the authors could mention this 
somewhere in the article. It could be early as a rationale for doing the study, or the Discussion in 
recognition of the different views.    
 
- Identifying the intervention results as ‘patient-preferred method’ is at times confusing (it is easily 
misunderstood as the mode of delivery). Alternatives could be ‘patient-based approach’, ‘patient-
generated materials’ or ‘patient-centred approach’.  
 
Abstract 
Background – rather than referring to ‘an increasing consensus’ the  ‘increasingly recognised as an 
essential component’ text mentioned in the Introduction in the main text seems easier to agree 
with.   
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Results – it would be better rephrase so that it is clear the results are specific to the TRUST trial 
participants rather than in general.  For example ‘TRUST patients want to receive…’ 
 
Results – it is stated that “TRUST participants (n=101) were randomised to the intervention.” Unless 
we have misunderstood something, this must be a mistake as this is the total available sample to 
be randomised so not all of them can get the intervention. Our guess is that 101 were involved in 
the SWAT evaluation and that 51 were randomised to the intervention. 
 
Conclusion – please rephrase “conduct PPI” to e.g. ‘We have demonstrated that it is feasible to 
involve PPI members in the development of result dissemination materials.’ 
  
Conclusion – The reference to age in “The study identified and developed a patient-preferred 
method of receiving clinical trial results for older adults over 65 years.” wasn’t part of the aim of 
the study as far as we can see and the authors should reconsider including it in the conclusion. If 
developing a strategy for the over 65s was a distinct aim of the study, then the text of study aims 
needs tweaked.    
 
Conclusion – it would be good if the authors could see if they can improve “,… it provides a record 
of the process of conducting PPI within the clinical trial setting.” We’re not entirely clear what is 
meant.  
  
Main text 
Methods – please ensure that the term used to denote the control/comparison group is consistent 
 throughout the paper as currently these terms are used interchangeably (also in tables and 
figures). 
 
In the results section it is stated that the PPI group consisted of three trial participants and one 
older adult. It would be good to give a sentence in Methods on how this ‘older adult’ was identified 
and recruited. 
 
The published protocol doesn’t say that the materials will also reviewed by the National Adult 
Literacy Agency (NALA). That this is an addition should be mentioned, along with why.  It’s not a 
problem, just that it would be good to be clear. 
  
Results  
Table 1 - Clarify the table title and include that it is the ‘characteristics of the trial participants 
stratified by participation in the different stages of the study’. 
 
Table 1 - Some of the column headings need clarification. 
 
“TRUST participants (n=104)” it should be clear these are the Irish TRUST sample only. It should 
also be noted that three participants were not eligible for the rest of the study as they took part in 
the PPI group. 
 
“Attended focus groups (n=19), Total sample n=38 RR=50%” it should be clear only 38 were 
invited/eligible or that this is a sub-sample of the 104. 
 
Please add an explanation of what RR is short for. 
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“Randomised into intervention (n=101)”, it should be clear n=101 were randomised (delete “into 
intervention”). See earlier comment about this.  It’s involved in SWAT evaluation that has n=101 as 
far as we can see, not randomised to intervention. 
  
Main text relating to figure 1 – please include the denominator in the parentheses as the 
percentages and n can be misleading on their own when small numbers are concerned.  
  
Figure 1 – in the title to figure 1, please clarify that patient understanding is presented by group. 
Please also include a short indication of how understanding was assessed (e.g. Likert scale). 
  
Table 2 – in the title include that this is presented by group and please also indicate how this was 
assessed (e.g. Likert scale). 
  
Any amendments which cannot be accommodated within the journal 15 word limit for the title of 
tables and figures could be added to a legend. 
  
In relation to the cost – it should also be clear that the NALA review is included in the cost. 
  
Discussion 
Paragraph 2 – please clarify the description of the intervention in relation to the literature as it 
currently confounds mode of delivery with only one type of material that can be posted to 
participants. 
  
Paragraph 3 – please change ‘negative reaction’ to ‘negative impact’ or similar – the reaction might 
be negative in researchers’ view but completely justified. You should also comment on the trial 
context in relation to this as the TRUST trial is relatively low risk compared to some of the trials 
cited. 
  
Paragraph 4 relates to the aim of the SWAT and should probably be moved to a bit earlier in the 
Discussion, paragraph 2 perhaps. 
   
Paragraph 5 and 6 (about cost) – The main message seems to be that PPI needs to be planned and 
costed appropriately – please be clear about this. We’re not sure this sentence is necessary “As the 
primary focus of this study was to carry out PPI, researchers carefully considered the costs at 
grant proposal stage and wrote these costs into the budget.” 
  
- The authors paid a fixed cost for travel costs for PPI participation rather than to cover 
participants’ time.  The UK’s INVOLVE has recommendations for covering PPI participants’ time 
and it might be nice to link these to the sentences that follow about the institutional difficulties of 
actually making these payments (which colleagues have experienced at our own institution). 
  
- Please include some consideration of the cost of carrying out the SWAT – is it a lot of money for a 
trial and is it money well spent? Please also consider that there may be some hidden costs e.g. 
expert input into questionnaire development an expert input in to the qualitative phase. This kind 
of expertise will not be available to all trials. 
  
Paragraph 7 (Limitations of the study) – The sample size of the SWAT was limited but to n=104 not 
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n=115 (11 had withdrawn before the SWAT started so were never eligible). 
  
Paragraph 8 (Limitations of the study) – Change “Secondly, all trial participants were aged 65 and 
over.” To ‘Secondly, all SWAT participants were aged 65 and over.’ While the former is true the 
SWAT did not include all trial participants. 
 
- Change “Alternative study populations may prefer…” to ‘Other trial populations may prefer…’ 
  
Paragraph 8 (Limitations of the study) – This paragraph actually highlights a strength of the SWAT 
which is that the PPI members consulted were participants in the trial. We’d suggest highlighting 
that many SWATs will be underpowered because they are generally unable to change the size of 
the host trial; they are made for meta-analysis really. 
  
Paragraph 10 – This is an important consideration. In relation to this it would be beneficial to 
include the research team’s reflection on what is the most appropriate primary outcome to 
measure regarding dissemination of trial results. The use of PPI clearly had an impact in that the 
TRUST trial would not have posted results to Irish participants at all if it had not been for this SWAT 
(i.e. the Press release control for the SWAT was more than planned for the trial without the SWAT).  
  
- It would be informative to have the authors comment on the difference in content of the two 
versions of the results used in the SWAT – was there a notable difference? 
 
- Would the authors in hindsight consider asking their PPI members what they think the primary 
outcome in the evaluation of the results materials should have been? 
What would the authors recommend for future evaluations of PPI impact? 
  
Paragraph 11 – It would be good to expand on “While this study provides a record of the process 
of conducting PPI as part of a SWAT, future research is needed to further develop PPI in clinical 
trial settings.” Any thoughts on what sort of PPI research?
 
Is the work clearly and accurately presented and does it cite the current literature?
Yes
Is the study design appropriate and is the work technically sound?
Yes
Are sufficient details of methods and analysis provided to allow replication by others?
Partly
If applicable, is the statistical analysis and its interpretation appropriate?
Partly
Are all the source data underlying the results available to ensure full reproducibility?
Yes
Are the conclusions drawn adequately supported by the results?
Partly
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This research article reports a Study Within A Trial (SWAT) hosted by the Thyroid 
Hormone Replacement for Subclinical Hypo-Thyroidism Trial (TRUST). The TRUST trial 
is an international trial and the SWAT was only conducted in one of the participating 
countries, namely Ireland. The purpose of the SWAT was to use a ‘Patient and Public 
Involvement (PPI) approach’ to identify and develop results reporting for the TRUST 
trial to its participants and subsequently evaluate the result materials. Evaluation of 
the result materials was carried out by assessing recipients’ understanding of the trial 
results compared to result materials as provided by the lead TRUST site. The SWAT 
protocol was published last year. 
  
Although the study is small and has some limitations it is an important piece in the 
result provision literature for trials, providing the detailed account of a thorough 
approach to the results provision process in trials. 
  
We have a few comments which should be addressed: 
  
Some people wonder why it is necessary to quantify at all the contribution public and 
patients make to a trial given that they are clearly trial stakeholders and we don’t do 
this for other stakeholders such as the statistician and the trial manager. Other 
people definitely do think it is necessary to quantify the gain from PPI. It would be 
good if the authors could mention this somewhere in the article. It could be early as a 
rationale for doing the study, or the Discussion in recognition of the different views.    
  
Firstly, thank you for your comprehensive comments. 
  
We agree this is a potentially contentious area. The following text has been added to the 
introduction of the manuscript as a rationale for doing the study. 
  
“Research funders increasingly expect that PPI is prioritised and resourced within studies. 
This increasing expectation has heightened the risk of researchers carrying out ‘tick-box’ PPI 
rather than ‘meaningful’ involvement (6). There are many moral and ethical arguments 
being made for PPI. Many believe that as citizens and taxpayers, members of the public 
have a right to influence research that is being funded by public money (7). PPI researchers 
are also making pragmatic arguments for PPI and providing anecdotal accounts about how 
PPI can make research more relevant, accessible and acceptable to participants (8). The 
ethical arguments are often seen as sufficient regardless of any pragmatic impact. 
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However, PPI costs time and money, therefore pragmatic claims need scrutiny (9). More 
substantive evidence is needed to evaluate the potential impact of PPI on the conduct and 
outcomes of research (5, 7)”. (Introduction, Paragraph 1) 
  
Identifying the intervention results as ‘patient-preferred method’ is at times 
confusing (it is easily misunderstood as the mode of delivery). Alternatives could be 
‘patient-based approach’, ‘patient-generated materials’ or ‘patient-centred approach’.  
  
We have made the following changes throughout the manuscript: 
  
“patient- preferred” has been changed to “patient-based”. 
“patient-preferred method” has been changed to “patient-based approach”. 
“Standard method” has been changed to “standard approach”. 
  
Abstract 
 
Background – rather than referring to ‘an increasing consensus’ the ‘increasingly 
recognised as an essential component’ text mentioned in the Introduction in the main 
text seems easier to agree with.   
 
There may be a slight misunderstanding here. The ‘increasing consensus’ phrase in the 
abstract refers to the sharing of results with participants. The ‘increasingly recognised as an 
essential component’ phrase in the introduction refers to PPI in clinical research. These 
phrases are referring to two different things. We believe it would be confusing to the reader 
to use the same phrase to refer to two separate issues. Therefore, we have not made any 
changes to address this comment. We hope this is acceptable. 
  
Results – it would be better rephrase so that it is clear the results are specific to the 
TRUST trial participants rather than in general.  For example ‘TRUST patients want to 
receive…’ 
  
This sentence in the abstract has been changed to: 
  
“TRUST patients want to receive…” (Abstract) 
  
Results – it is stated that “TRUST participants (n=101) were randomised to the 
intervention.” Unless we have misunderstood something, this must be a mistake as 
this is the total available sample to be randomised so not all of them can get the 
intervention. Our guess is that 101 were involved in the SWAT evaluation and that 51 
were randomised to the intervention. 
  
The sentence in the abstract has been corrected:  
  
“TRUST participants (n=101) were randomised to the either the intervention (n=51) or 
control group (n=50).” (Abstract) 
  
Conclusion – please rephrase “conduct PPI” to e.g. ‘We have demonstrated that it is 
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feasible to involve PPI members in the development of result dissemination 
materials.’ 
  
We have changed this sentence in the abstract as suggested: 
  
“We have demonstrated that it is feasible to involve PPI partners in the development of 
result dissemination materials.” (Abstract) 
  
We have also changed the same sentence in the main manuscript as following: 
  
“We have demonstrated that it is feasible to involve PPI partners in the development of 
result dissemination materials.” (Conclusion, Paragraph 1) 
  
Conclusion – The reference to age in “The study identified and developed a patient-
preferred method of receiving clinical trial results for older adults over 65 years.” 
wasn’t part of the aim of the study as far as we can see and the authors should 
reconsider including it in the conclusion. If developing a strategy for the over 65s was 
a distinct aim of the study, then the text of study aims needs tweaked.    
  
The aim of the study has been changed to clarify that all TRUST participants were aged 65 
and over: 
  
“”The aim of this Study Within A Trial (SWAT) is to use a patient and public involvement (PPI) 
approach to identify, develop and evaluate a patient-based approach to receiving trial 
results for participants in the Thyroid Hormone Replacement for Subclinical Hypo-
Thyroidism Trial (TRUST), a trial of thyroxine versus placebo in people aged 65 years and 
older” (Abstract) 
                
The conclusion has been changed to reflect the aim: 
“The study identified, developed and evaluated a patient-based approach to receiving 
results for trial participants.” (Abstract) 
  
  
Conclusion – it would be good if the authors could see if they can improve “,… it 
provides a record of the process of conducting PPI within the clinical trial setting.” 
We’re not entirely clear what is meant.  
  
We have made changes to this sentence in both the abstract and the main manuscript to 
cliarfiy the conclusion:  
“… it documents the process of conducting PPI within the clinical trial setting. This process 
may be useful for other trialists interested in conducting and evaluating the impact of PPI in 
clinical trials.” (Abstract, Discussion, Paragraph 11 and Conclusion, Paragraph 1) 
  
Main text 
 
Methods – please ensure that the term used to denote the control/comparison group 
is consistent  throughout the paper as currently these terms are used interchangeably 
HRB Open Research
 
Page 35 of 43
HRB Open Research 2019, 1:14 Last updated: 10 SEP 2020
(also in tables and figures). 
  
To ensure consistency, the word ‘comparison’ has been changed to ‘control’ throughout the 
manuscript. 
  
In the results section it is stated that the PPI group consisted of three trial 
participants and one older adult. It would be good to give a sentence in Methods on 
how this ‘older adult’ was identified and recruited. 
  
The following sentence has been added to the manuscript to give more detail on how the 
older adult was identified: 
  
“In addition to these three PPI partners, an additional partner was identified from a 
previous qualitative research study undertaken by the research team. This older adult was 
keen to learn more about research and expressed an interested in being involved in future 
projects. While this individual had previous experience of taking part in research (as an 
interview participant), she had no experience of taking part in a clinical trial or being 
involved as a PPI partner”. (Methods: PPI group) 
  
The published protocol doesn’t say that the materials will also reviewed by the 
National Adult Literacy Agency (NALA). That this is an addition should be mentioned, 
along with why.  It’s not a problem, just that it would be good to be clear. 
  
We have inserted two additional sentences into the manuscript to clarify: 
  
Sentence 1: While the PPI group had significant input into the format and language used in 
the patient-based approach, the research team felt that it would be of additional benefit to 
collaborate with the National Adult Literacy Agency (NALA) to ensure the document adhered 
to national “Plain English” standards. (Methods: Adult Literacy Review) 
  
Sentence 2: Although the review was taken as an additional step to the published protocol 
for the study, the research team felt it was helpful to further ensure that the document was 
accessible and easy to understand. (Methods: Adult Literacy Review) 
  
Results  
 
Table 1 - Clarify the table title and include that it is the ‘characteristics of the trial 
participants stratified by participation in the different stages of the study’. 
  
The table title has been clarified: 
  
“Table 1: Characteristics of trial participants stratified by participation in the different stages 
of the study”. (Results: Table 1) 
  
Table 1 - Some of the column headings need clarification. 
“TRUST participants (n=104)” it should be clear these are the Irish TRUST sample only. 
It should also be noted that three participants were not eligible for the rest of the 
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study as they took part in the PPI group. 
  
The first column heading has been changed to: 
  
“Total Irish TRUST participants (n=104)” (Results: Table 1) 
  
A footnote has been added below the table to clarify this: 
  
3 Total Irish TRUST participants (n=104) excluding PPI partners (n=3)= n=101. (Results: Table 
1) 
  
“Attended focus groups (n=19), Total sample n=38 RR=50%” it should be clear only 38 
were invited/eligible or that this is a sub-sample of the 104. 
  
A footnote has been added to the table to clarify this: 
  
1A subgroup of Irish TRUST participants (n=38) were invited to focus groups. (Results: Table 
1) 
  
Please add an explanation of what RR is short for. 
  
A footnote has been added to the table to clarify this. ` 
  
2RR=Response Rate (Results: Table 1) 
  
“Randomised into intervention (n=101)”, it should be clear n=101 were randomised 
(delete “into intervention”). See earlier comment about this.  It’s involved in SWAT 
evaluation that has n=101 as far as we can see, not randomised to intervention. 
  
Yes, we agree that this needs to be clearer.  We have deleted ‘to intervention’ as you have 
suggested. 
  
Main text relating to figure 1 – please include the denominator in the parentheses as 
the percentages and n can be misleading on their own when small numbers are 
concerned.  
  
The main text relating to figure has now been changed to include the denominator in the 
parentheses. 
  
Figure 1 – in the title to figure 1, please clarify that patient understanding is presented 
by group. Please also include a short indication of how understanding was assessed 
(e.g. Likert scale). 
  
The title of Figure 1 has been changed to: 
  
“Patient understanding of primary aim, side effect and trial result of the TRUST Thyroid Trial 
presented by group.” (Results: Figure 1) 
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A footnote has been added to the Figure 1 title to clarify how understanding was assessed. 
The footnote reads: 
  
“1 Patient understanding of primary aim, side effect and trial results was assessed using 
multiple choice questions.” (Results: Figure 1) 
  
Table 2 – in the title include that this is presented by group and please also indicate 
how this was assessed (e.g. Likert scale). 
The title for Table 2 has been changed in the manuscript to: 
  
“Table 2: Patient perceptions of understanding presented by group.” (Results: Table 2) 
A footnote has been added to the title to clarify how perceptions of understandings were 
assessed. The footnote reads: 
  
“Patient perceptions of understanding were assessed using a five point LIKERT scale.” 
(Results: Table 2) 
  
Any amendments which cannot be accommodated within the journal 15 word limit for 
the title of tables and figures could be added to a legend. 
  
Thank you for this suggestion. 
  
In relation to the cost – it should also be clear that the NALA review is included in the 
cost. 
            
The following sentence has been added to make it clear that the NALA review is included in 
the cost:  
  
These costs included researcher salary, travel and expenses for PPI participants, adult 
literacy review and printing/postage costs. (Methods: Costs of conducting PPI) 
  
Discussion 
 
Paragraph 2 – please clarify the description of the intervention in relation to the 
literature as it currently  
confounds mode of delivery with only one type of material that can be posted to 
participants. 
 
            The following text has been added to this paragraph to clarify the description of the 
literature cited: 
  
“A previous study investigating the preferences of individuals taking part in a cardiac 
rehabilitation trial found that 80% of trial participants (mean age 68.5 years) preferred to 
receive the results by post (22)” (Discussion, Paragraph 3) 
  
Paragraph 3- please change ‘negative reaction’ to ‘negative impact’-the reaction might 
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be negative in researchers’ view but completely justified. You should also comment on 
the trial context in relation to this as the TRUST trial is relatively low risk compared to 
some other trials cited.  
  
We have changed the phrasing of ‘negative reaction’ to ‘negative impact’ and added the 
following sentence: 
  
“Previous studies exploring participants’ reactions found that sharing trial results with 
participants can cause some negative impacts such as anxiety, anger, guilt, upset and 
confusion (23-25). As far as researchers in this study are aware, providing results did not 
cause any negative impacts. This may have been due to the fact that the TRUST trial had a 
low risk of morbidity or mortality compared to some of the other studies citing negative 
impacts.” (Discussion, Paragraph 4) 
  
Paragraph 4 relates to the aim of the SWAT and should probably be moved to a bit 
earlier in the Discussion, paragraph 2 perhaps. 
  
Paragraph 4 has been moved to the first paragraph of the discussion. 
  
Paragraph 5 and 6 (about cost) – The main message seems to be that PPI needs to be 
planned and costed appropriately – please be clear about this. We’re not sure this 
sentence is necessary “As the primary focus of this study was to carry out PPI, 
researchers carefully considered the costs at grant proposal stage and wrote these 
costs into the budget.” 
  
Yes this is the main message. We have deleted the sentence as suggested and added the 
following sentence to the paragraph: 
  
“It is extremely important that researchers plan PPI at the grant proposal stage and 
estimate the costs appropriately.” (Discussion, Paragraph 5) 
  
The authors paid a fixed cost for travel costs for PPI participation rather than to cover 
participants’ time.  The UK’s INVOLVE has recommendations for covering PPI 
participants’ time and it might be nice to link these to the sentences that follow about 
the institutional difficulties of actually making these payments (which colleagues 
have experienced at our own institution). 
  
We have edited the text in this paragraph to include a reference to INVOLVE’s payment 
policy: 
  
“INVOLVE, the national advisory group supporting active public involvement in health 
services, public health and social care research in the UK, have recommended that PPI 
partners should be paid for their involvement (30). Despite this, existing research suggests 
that institutional difficulties make negotiating the mechanisms of paying participants very 
difficult (32).” (Discussion, Paragraph 6) 
  
Please include some consideration of the cost of carrying out the SWAT – is it a lot of 
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money for a trial and is it money well spent? Please also consider that there may be 
some hidden costs e.g. expert input into questionnaire development an expert input 
in to the qualitative phase. This kind of expertise will not be available to all trials. 
  
We have inserted the following text into the manuscript to address this: 
  
“This breakdown provides a template to other researchers who plan to carry out and 
evaluate PPI as part of their research. It is important to note that not all costs associated 
with carrying out the study were included in this amount. For example, the only salary 
costed was that of the research assistant. The expertise provided by other members of the 
study team were not included in the total cost as they were being paid by the University or 
other research grants. The total cost of conducting this study was €8,049 which is not 
insignificant but should be considered in the context of the cost of large scale trials.” 
(Discussion, Paragraph 6) 
  
Paragraph 7 (Limitations of the study) – The sample size of the SWAT was limited but 
to n=104 not n=115 (11 had withdrawn before the SWAT started so were never eligible). 
  
We have changed the sample size to n=104. (Discussion: Strengths and Limitations, 
Paragraph 2) 
  
Paragraph 8 (Limitations of the study) – Change “Secondly, all trial participants were 
aged 65 and over.” 
To ‘Secondly, all SWAT participants were aged 65 and over.’ While the former is true 
the SWAT did not include all trial participants. 
  
We have changed the manuscript as suggested. (Discussion: Strengths and Limitations, 
Paragraph 3) 
  
Change “Alternative study populations may prefer…” to ‘Other trial populations may 
prefer…’ 
We have changed the manuscript as suggested. 
  
Paragraph 8 (Limitations of the study) – This paragraph actually highlights a strength 
of the SWAT which is that the PPI members consulted were participants in the trial. 
We’d suggest highlighting that many SWATs will be underpowered because they are 
generally unable to change the size of the host trial; they are made for meta-analysis 
really. 
This section of the discussion has been reworded from ‘Limitations of the study’ to 
‘Strengths and limitations of the study’ (Discussion) 
  
This paragraph in question has been rephrased as a highlight of the SWAT and moved to 
the first paragraph in the ‘Strengths and limitations of the study’ section. It now reads as 
following: 
  
“While this study provides important insights into patients’ preferences of receiving trial 
results, it is not without limitations. Firstly, existing PPI literature states that ‘to understand 
HRB Open Research
 
Page 40 of 43
HRB Open Research 2019, 1:14 Last updated: 10 SEP 2020
the research needs and challenges, PPI has to engage people who are able to offer 
perspectives from the study population’ (3). All PPI partners in this study were active 
members of the research community as they had taken part in the TRUST trial and had 
agreed to long-term follow up. This is a strength of the SWAT as they were able to offer 
perspectives from the study population, however it does have an important implication for 
their reporting of understanding the results of the trial. They may be more inclined to rate 
their understanding as high because of their investment in the trial (31), thus potentially 
minimising differences between the intervention and control conditions and minimising 
inferences that can be drawn about the intervention.” 
  
Paragraph 10 – This is an important consideration. In relation to this it would be 
beneficial to include the research team’s reflection on what is the most appropriate 
primary outcome to measure regarding dissemination of trial results. The use of PPI 
clearly had an impact in that the TRUST trial would not have posted results to Irish 
participants at all if it had not been for this SWAT (i.e. the Press release control for the 
SWAT was more than planned for the trial without the SWAT).  
  
We agree that PPI had an important role to play in ensuring that participants actually 
received the results of the trial and other primary outcome measures could have been used 
to evaluate the impact of PPI. If we had involved PPI partners from the outset of this study, 
relevant outcome measures could have been co-developed by researchers and PPI partners. 
We have added this important point to the discussion as following: 
  
The primary outcome of this study was assessing the impact of PPI on patient 
understanding of results, however, this was not the only potential impact. In hindsight, we 
adopted a limited approach to PPI in this study as we did not involve our PPI partners from 
the outset of the SWAT. Involving PPI partners in the design of the SWAT could have 
identified other appropriate primary outcome measures which would be more relevant to 
evaluating the impact of PPI in clinical trials (39). (Discussion: Strengths and Limitations, 
Paragraph 4) 
 
It would be informative to have the authors comment on the difference in content of 
the two versions of the results used in the SWAT – was there a notable difference? 
  
Both versions of the results have been uploaded as supplementary files and are accessible 
on the HRB Open platform. 
  
“The intervention group (n=51) received the patient-based letter format (see Supplementary 
File 3: Final version patient-based results letter) and the control group (n=50) received a 
copy of the TRUST results press release, which was made available by the lead study site on 
the TRUST Thyroid Trial Website (see Supplementary File 4: Standard results letter).” 
(Results: Phase Two) 
  
We have added a discussion on the difference in content of the versions of the results: 
  
“It is also important to point out that the control group in this study received a copy of the 
trial results in a press release format. Most trial participants do not receive this.  While this 
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control method was a step further than normal procedure, the researchers in this study felt 
this was appropriate. The information presented in the press release was similar to that of 
the patient-based approach. However, the format and layout of the press release was 
different. Information was written in four long paragraphs separated by individual 
headings.  It was also much shorter (1 page in total) than the patient-based approach (3 
pages in total). Given the fact that press releases are written by public relations 
professionals with a view to communicating effectively and efficiently, this again may have 
potentially minimised differences between the intervention and control conditions.” 
(Discussion: Strengths and Limitations, Paragraph 4) 
  
Would the authors in hindsight consider asking their PPI members what they think 
the primary outcome in the evaluation of the results materials should have been? 
  
Yes. This is a very important suggestion. We have inserted the following text into the 
manuscript: 
  
The primary outcome of this study was assessing the impact of PPI on patient 
understanding of results, however, this was not the only potential impact. In hindsight, we 
adopted a limited approach to PPI in this study as we did not involve our PPI partners from 
the outset of the SWAT. Involving PPI partners in the development of core outcome sets for 
this SWAT could have identified other more appropriate primary outcome measures (39). 
(Discussion: Strengths and Limitations, Paragraph 4) 
  
What would the authors recommend for future evaluations of PPI impact? 
  
We have considered our recommendations for future evaluations of PPI impact and have 
inserted the following text into the manuscript: 
  
Evaluating the impact of PPI can be resource intensive, especially if PPI impact is not the 
primary aim of a study. As there is currently no gold standard or comprehensive guidelines 
for researchers to follow when evaluating the impact of PPI, further research is needed. This 
research should involve PPI partners in the development of core outcome sets for 
evaluating PPI impact. This would significantly enhance the literature in the area. 
(Discussion: Strengths and Limitations, Paragraph 5)  
  
  
Paragraph 11 – It would be good to expand on “While this study provides a record of 
the process of conducting PPI as part of a SWAT, future research is needed to further 
develop PPI in clinical trial settings.” Any thoughts on what sort of PPI research? 
 
We have added our thoughts on the sort of PPI research needed in the discussion: 
  
Evaluating the impact of PPI can be resource intensive, especially if PPI impact is not the 
primary aim of a study. As there is currently no gold standard or comprehensive guidelines 
for researchers to follow when evaluating the impact of PPI, further research is needed. This 
research should involve PPIpartners in the development of core outcome sets for evaluating 
PPI impact. This would significantly enhance the literature in the area. (Discussion: 
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Strengths and Limitations, Paragraph 5)  
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